About Us

About Us

History

2024
03

T.O.P. NK monotherapy Ph1/2a IND change approval

02

T.O.P. NK Ph1 interim result ASCO 2024 publication

2023
05

T.O.P. NK Ph1 initiation (Multi-center, All comers)

04

Drone Treg Selected for Government-initiated Drug Development Program (Korean Fund for Regenerative Medicine)

T.O.P. NK FIH monotherapy Ph1 IND approval

2022
12

Permission for Management Business of Human Body Cells

Research license and option agreement with Optieum Biotechnologies

11
Presented preclinical data of T.O.P. NK at SITC 2022
08

Partnership with HK Inno.N to research and develop CAR-NK

Partnership with Cartexell(a subsidiary of Helixmith) to research and develop CAR-NK

06
ISO27001(Information Security Management System) certified
03

MOU with Yonsei University health system & GI-Innovation

Korea Intellectual Property Office(KIPO) certified excellent intellectual property managing company(IPCERT)

02
Succeed 200L cultivation for T.O.P. NK (Feeder-free)
01

Patent registration of Nano Block Co-polymer Unit Material (Korea)

Patent registration of methods and compositions for T.O.P. NK (Korea)

2021
12
Permission for Manufacturing Advanced Biological Products
09
Strategic investment(20 million USD)
06

Completion of GMP facility

Series B financing(48 million USD)

05
MOU with Ewha University Medical Center
03

Korea Intellectual Property Office(KIPO) certified excellence company in employee invention promotion

01

MOU with International Vaccine Institute(IVI)

MOU with Severance hospital

MOU with GI-BIOME

2020
12
Awardee of ‘Cytiva Korea CEO award’ at the 2020 Bio Challenge
10
Success in Scale-up to 50L of T.O.P. NK
07
Research Collaboration with Miltenyi Biotec Inc.
06
Series A financing(26 million USD)
04
Nano NK research on the cover of Advanced Material Journal (IF=30.85)
2019
07
Non-exclusive agreement of GI-101
05
Registration of our affiliate R&D center
02
Accreditation as a bio-venture
01
In-licensing of Nano NK cell
2018
10

In-licensing for Drone Treg cell

Foundation of GI-Cell